Predictions of 2018 pharma M&A surge fall flat, but patent licensing deals are at a record high

Despite forecasts of a sharp rise in pharma deal-making activity, it has proved to be a slow year on the M&A front. One reason may be that licensing partnerships are proving far more popular than many had expected.


Get unlimited access to all IAM content